|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||4.1500 - 4.1500|
|52 Week Range||1.3000 - 5.3000|
|Beta (5Y Monthly)||1.56|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jun 05, 2017|
|1y Target Est||N/A|
GenScript Biotech Corporation (HKEX: 1548.HK), a leading global technology and service provider of life science R&D and manufacture, today reported its first half 2021 financial results for the six months ended June 30. It also announced that the Group has expanded its presence in the gene and cell therapy (GCT) industry, with aggressive investments from the Group's life science services and products business, biologics CDMO business, and cell therapy business.
Genscript Biotech (HKEX: 1548.HK) (GenScript), a global leading biotech company, today announced its audited financial results for the year ended June 30, 2021.
GenScript Biotech Corporation (Stock Code: 1548.HK) today announced a collaboration with Allozymes, a synthetic biology company transforming ingredient manufacturing by unlocking protein engineering potential through groundbreaking technologies. In this partnership, GenScript will provide the mutant libraries construction to Allozymes for their downstream applications across various industries including pharmaceuticals, cosmetics and food & beverage.